Cargando…

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0–1 were treated with eribulin-LF either on day 1 every 21 days...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461749/ https://www.ncbi.nlm.nih.gov/pubmed/30679780 http://dx.doi.org/10.1038/s41416-019-0377-x

Ejemplares similares

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
por: Kenny, Laura, et al.
Publicado: (2022)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
por: Shitara, Kohei, et al.
Publicado: (2023)

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
por: Kristeleit, Rebecca, et al.
Publicado: (2020)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations
por: Ko, Joungbo, et al.
Publicado: (2023)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
por: Board, Ruth E, et al.
Publicado: (2008)

Pharmacokinetics of a liposomal formulation of doxorubicin in rats
por: Liu, Zongyu, et al.
Publicado: (2017)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022)

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer
por: Udagawa, Hibiki, et al.
Publicado: (2022)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Systemic Protein Delivery via Inhalable Liposomes: Formulation and Pharmacokinetics
por: Ponkshe, Pranav, et al.
Publicado: (2023)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Formulation and Evaluation of Celastrol-Loaded Liposomes
por: Song, Jie, et al.
Publicado: (2011)

Development and characterization of liposomal formulation of bortezomib
por: Deshantri, Anil K., et al.
Publicado: (2019)

Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin
por: Wang, Tiechuang, et al.
Publicado: (2012)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin.
por: Gabizon, A., et al.
Publicado: (1991)

Formulations, Hemolytic and Pharmacokinetic Studies on Saikosaponin a and Saikosaponin d Compound Liposomes
por: Zhang, Guo-Song, et al.
Publicado: (2015)

Design and Evaluation of Liposomal Formulation of Pilocarpine Nitrate
por: Rathod, S., et al.
Publicado: (2010)

Formulation and Evaluation of Liposomes for Transdermal Delivery of Celecoxib
por: Moghimipour, Eskandar, et al.
Publicado: (2015)

Liposomal Formulations in Clinical Use: An Updated Review
por: Bulbake, Upendra, et al.
Publicado: (2017)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Magneto-Liposomes as MRI Contrast Agents: A Systematic Study of Different Liposomal Formulations
por: Kostevšek, Nina, et al.
Publicado: (2020)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

In vitro radiosensitization by eribulin in human cancer cell lines
por: Benlloch, Raquel, et al.
Publicado: (2022)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t85lbj9923dk96e11iiv2m79t2